Researchers have discovered that the amniotic fluid has a high concentration of regenerative cells, even more so than bone marrow in adults. During proceedings at an FDA regulated lab, the biologic material ends up containing significant regenerative properties, such as growth factors, hyaluronic acid and stem cell activators called exosomes. Interestingly, amniotic fluid is actually immunoprivileged, so it does not create a rejection reaction when injected into a patient. Acts by signaling endogenous resident cells to reduce chronic inflammation and promote regrowth of new tissue. Amnion-derived fluid also contains a wide range of growth factors, including VEGF, bFGF, EGF, TGF-β1, among many others. Offers less chair time post-procedure compared to similar products.